Codagenix

Center, Nebraska, United States, 11794

Company profile

Codagenix company profile

Codagenix is a developer of live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus. Its vaccines utilize Synthetic Attenuated Virus Engineering (SAVE), which are based on synthetic biology and are rationally re-designed of the entire genome to yield a vaccine strain.

Business identity

Website: http://codagenix.com
Contact email: [email protected]
Phone number: 5168290353
Operating status: Active
Company type: For Profit
Employee range: 1-10 employees
Revenue range: $0-$1M
Founded: 2011-08-01

LinkedIn Facebook X

Headquarters

Headquarters: Center, Nebraska, United States
Postal code: 11794
Country code: US
Continent: North America

Capital profile

Funding and company signals

Funding stage: Early Stage Venture
Funding rounds: 12
Total equity funding: $50.1M
Last funding: Grant / $5.9M / 2023-10-24
Last equity funding: Series B / $25M
Investors: 9
Lead investors: 8
Founders: 3
Articles: 28

Categories and groups

Biotechnology Genetics Medical Biotechnology Health Care Science and Engineering

Founders and investors

Founders

Eckard WimmerJ. Robert ColemanSteffen Mueller

Lead investors

Accelerate Long IslandAdjuvant CapitalNational Institute of Allergy and Infectious DiseasesNational Institutes of HealthSerum Institute of India Pvt. Ltd.the Long Island Emerging technologies Fund (LIETF)Topspin PartnersU.S. Department of Defense

Investors

Adjuvant CapitalNational Institutes of HealthSerum Institute of India Pvt. Ltd.Topspin PartnersU.S. Department of Defense